Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.57 |
| ▸ | CDC25B | P30305 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594709 | 0.90 | CDC25B (0.66) | IDO1CDC25BMEN1GAAMAPT | |
| SCHEMBL8931188 | 0.85 | IDO1 (0.68) | IDO1CDC25BEP300KAT2BKAT8 | |
| SCHEMBL11840391 | 0.85 | IDO1 (0.58) | IDO1CDC25BMEN1GAAMAPT | |
| SCHEMBL25452370 | 0.83 | ADRA2A (0.56) | IDO1CDC25BMEN1GAAMAPT | |
| SCHEMBL2208086 | 0.82 | GAA (0.50) | CDC25BMEN1GAAMAPTKMT2A | |
| SCHEMBL4595187 | 0.80 | CDC25B (0.73) | IDO1CDC25BMEN1GAAMAPT | |
| SCHEMBL11809694 | 0.80 | MEN1 (0.76) | IDO1CDC25BMEN1GAAMAPT | |
| SCHEMBL7954056 | 0.78 | CDC25B (0.71) | CDC25BMEN1GAAMAPTKMT2A | |
| SCHEMBL1921924 | 0.78 | MAPT (0.60) | MEN1GAAMAPTKMT2ATDP1 | |
| SCHEMBL6760764 | 0.77 | MAPT (0.55) | MEN1GAAMAPTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | claimed |
| EP-1937243-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-07-02 | — | — | EP | claimed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | claimed |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
| EP-1937243-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | APP, BACE1, SNCA | IDO1 2712/4885CDC25B 2914/4885MEN1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.